CONCORD, N.C. — Michigan-based pharmaceutical company Esperion Therapeutics will be a primary sponsor for both RFK Racing entries throughout the NASCAR Cup Series season.
The two sides reached a multi-year agreement where Esperion will promote two cholesterol lowering treatments – NEXLIZET (bempedoic acid and ezetimibe) and NEXLETOL (bempedoic acid).
NEXLIZET will be featured on Brad Keselowski’s No. 6 Ford at this year’s Daytona Speedweeks, including the famed Daytona 500 on February 19.
NEXLETOL will be featured throughout the season on Chris Buescher’s No. 17 Ford.
“We’re thrilled to have Esperion, a company that is making waves in the pharmaceutical industry, on board with us,” said Steve Newmark, President of RFK Racing. “We look forward to working with Esperion to create engaging content around their two products in NEXLIZET and NEXLETOL and showcasing their debut on the No. 6 for the famed Daytona 500. We’re thankful to the team at Esperion and can’t wait to introduce them to the sport in a big way in 2023.”
In addition to the Daytona 500, Esperion will serve as a primary on the No. 6 Ford at the All-Star Race at North Wilkesboro Speedway and RFK’s home track at Michigan.
The brand will serve as a primary sponsor on the No. 17 at Las Vegas, Martinsville (Va.) Speedway in April and Martinsville (Va.) Speedway in the Fall.
“We’re excited to partner with RFK Racing to increase brand awareness, and this sponsorship provides ample opportunities for community engagement and education to their large and diverse consumer base to advance awareness about the benefits of lowering LDL cholesterol and improving cardiovascular health,” said Sheldon Koenig, Esperion’s President and CEO.
